ProstaLund AB
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more
ProstaLund AB (PLUN) - Total Assets
Latest total assets as of June 2025: Skr55.84 Million SEK
Based on the latest financial reports, ProstaLund AB (PLUN) holds total assets worth Skr55.84 Million SEK as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ProstaLund AB - Total Assets Trend (2012–2024)
This chart illustrates how ProstaLund AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ProstaLund AB - Asset Composition Analysis
Current Asset Composition (December 2024)
ProstaLund AB's total assets of Skr55.84 Million consist of 42.9% current assets and 57.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 12.7% |
| Accounts Receivable | Skr4.28 Million | 6.9% |
| Inventory | Skr14.35 Million | 23.3% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr34.38 Million | 55.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how ProstaLund AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProstaLund AB's current assets represent 42.9% of total assets in 2024, a decrease from 56.9% in 2012.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2024, up from 10.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 24.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 55.8% of total assets.
ProstaLund AB Competitors by Total Assets
Key competitors of ProstaLund AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xian International Medical Investment Co Ltd
SHE:000516
|
China | CN¥9.79 Billion |
|
Meinian Onehealth Healthcare Holdings Co Ltd
SHE:002044
|
China | CN¥19.57 Billion |
|
Hengkang Medical Group Co Ltd
SHE:002219
|
China | CN¥6.55 Billion |
|
TMC Life Sciences Bhd
KLSE:0101
|
Malaysia | RM1.12 Billion |
|
Optimax Holdings Sdn Bhd
KLSE:0222
|
Malaysia | RM146.00 Million |
|
Cengild Medical Berhad
KLSE:0243
|
Malaysia | RM218.07 Million |
|
DC HEALTHCARE HOLDINGS BERHAD
KLSE:0283
|
Malaysia | RM99.33 Million |
|
Raffles Medical Group Ltd
F:02M1
|
Germany | €1.49 Billion |
ProstaLund AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ProstaLund AB generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ProstaLund AB is currently not profitable relative to its asset base.
ProstaLund AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 2.06 | 5.03 |
| Quick Ratio | 0.59 | 0.76 | 3.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr8.62 Million | Skr 12.49 Million | Skr 17.16 Million |
ProstaLund AB - Advanced Valuation Insights
This section examines the relationship between ProstaLund AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.07 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | Skr61.64 Million |
| Market Capitalization | $576.77K USD |
Valuation Analysis
Below Book Valuation: The market values ProstaLund AB's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ProstaLund AB's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProstaLund AB (2012–2024)
The table below shows the annual total assets of ProstaLund AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr61.64 Million | -5.91% |
| 2023-12-31 | Skr65.51 Million | +28.34% |
| 2022-12-31 | Skr51.04 Million | +17.39% |
| 2021-12-31 | Skr43.48 Million | +41.00% |
| 2020-12-31 | Skr30.84 Million | +16.86% |
| 2019-12-31 | Skr26.39 Million | +37.76% |
| 2018-12-31 | Skr19.16 Million | +6.87% |
| 2017-12-31 | Skr17.92 Million | -49.13% |
| 2016-12-31 | Skr35.23 Million | +30.00% |
| 2015-12-31 | Skr27.10 Million | +70.93% |
| 2014-12-31 | Skr15.86 Million | +64.98% |
| 2013-12-31 | Skr9.61 Million | +39.01% |
| 2012-12-31 | Skr6.91 Million | -- |